Novartis

NYSE: NVS
$88.85
-$0.69 (-0.8%)
Closing price January 19, 2022
Wednesday’s early top analyst upgrades and downgrades included Albertsons, AppLovin, Array Technologies, eBay, Freeport-McMoRan, GameStop, Melco Resorts, Navitas Semiconductor, Nike and Novartis.
Shares of five top established and mature biotechnology and pharmaceutical companies have been hit hard and are offering some of the best entry points in months. The stocks also are rated Buy at top...
With the potential for far lower returns in the coming year, total return becomes a key ingredient for investment success. These five top health care stocks look like very solid ideas for 2022, as...
These five top stocks on the Goldman Sachs European Conviction List all trade on American exchanges, have liquidity and pay very dependable dividends. They are outstanding total return ideas now and...
24/7 Wall St. screened the top European Dividend Aristocrats looking for the most liquid and well-known names for investors seeking income and a degree of diversification away from the American...
Monday's top analyst upgrades and downgrades included Adobe, Analog Devices, Big Lots, Colgate-Palmolive, Novartis, Salesforce.com and Workday.
Here are four companies with huge market caps that pay big dividends and have for a long time.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including DraftKings, H&R Block and Novartis.
Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news, though, was lurking in Nevada federal district court.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
Tuesday's top analyst upgrades, downgrades and initiations included Aurora Cannabis, Biogen, EverQuote, Micron Technology, Nio, Nvidia, Palo Alto Networks, Tandem Diabetes Care, Tesla and Wix.com.
24/7 Wall St. screened the Merrill Lynch health care research database looking for large pharmaceutical leaders that also pay solid and dependable dividends. These five make sense for growth and...
Medicines Co shares shot up on Monday after it was reported that Novartis will be acquiring the firm. The transaction was unanimously approved by the boards of directors of both companies.
Medicines shares shot up on Tuesday after it was reported that Novartis might be eyeing this company as its newest acquisition.
The top analyst upgrades, downgrades and initiations seen on Wednesday included DowDuPont, Electronic Arts, Estee Lauder, Exxon, Generac, Match, Nasdaq, Novartis, PayPal, Snap and Vishay.